OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy
| Autor: | Raffaele Bruno, Paola Nasta, Massimo Puoti, Amedeo Capetti, E. Raise, Massimo Galli, Claudio Iannacone, Giuseppe Cariti, G. Palmieri, Veronica Ravasio |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Genotype Hepatitis C virus Subgroup analysis HIV Infections Hepacivirus medicine.disease_cause Gastroenterology Polyethylene Glycols chemistry.chemical_compound Pegylated interferon Interferon Internal medicine Ribavirin medicine Odds Ratio Humans Prospective Studies Hepatology business.industry Coinfection virus diseases Interferon-alpha Odds ratio Hepatitis C medicine.disease digestive system diseases Recombinant Proteins chemistry Italy Immunology RNA Viral Drug Therapy Combination business Peginterferon alfa-2a medicine.drug |
| Zdroj: | Liver international : official journal of the International Association for the Study of the Liver. 35(1) |
| ISSN: | 1478-3231 |
| Popis: | Background & Aims Hepatitis C virus (HCV) genotype 3 (G3) is common among HIV/HCV co-infected individuals and associated with moderate sustained virological response (SVR) rates with pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy, while G2 is less frequent and associated with higher SVR. To determine SVR and other response rates, identify SVR predictors and analyse differences between G2 and G3 with PEG-IFN/RBV in a large HIV/HCV G2/3 patient population. Methods This subgroup analysis of the prospective, observational OPERA (Optimized Pegylated interferon Efficacy and anti-Retroviral Approach) study was conducted between 2005 and 2011 in Italy in PEG-IFN/RBV-naive HIV/HCV patients. The primary efficacy endpoint was SVR rate (HCV RNA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text